2例妊娠期原发性血小板增多症的合理用药分析  

Anaylysis of Rational Medication to Two Patients with Essential Thrombocythemia during Gestation Period

作　　者：孙婉玲[1] 苏力[1] 周齐[1] 

机构地区：[1]首都医科大学宣武医院,北京100053

出　　处：《中国药物警戒》2015年第8期503-505,共3页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(81000200);北京市卫生系统高层次卫生技术人才培养项目(2011-3-092);首都医科大学基础临床科研合作基金课题(15JL-L07)

摘　　要：目的总结分析2例原发性血小板增多症患者妊娠期及围产期的治疗过程,并进行相关文献复习。方法评估2例妊娠原发性血小板增多症患者,根据患者危险度分层,在妊娠期及围产期分别给予个体化治疗。结果 1例高危患者妊娠期全程给予低分子肝素及干扰素α-2 b治疗,另1例低危患者妊娠期全程给予阿司匹林及干扰素α-2 b治疗;2例患者均安全娩出胎儿,产后12小时应用低分子肝素至围产期结束。结论原发性血小板增多患者妊娠期及围产期极易出现各种并发症,需在血液科和产科医生的合作下,根据患者危险度分层给予全程个体化治疗、合理用药。Objective To present the treatment of two essential thrombocythemia （ET） patients during gestation period and perinatal period, and analyze the rational medication. Methods Evaluated two ET patients, and individualized ther-apies were given during the gestation period and perinatal period according to the risk stratification. Results To the high risk patient, low molecular weight heparin （LMWH） and interferon α-2 b were applied during the whole ges-tation period; to the low risk patient, aspirin and interferon α-2 b were applied during the whole gestation period. Both patients delivered the fetus successfully, and LMWH was used from 12 hours to 6 weeks after delivery. Conclu-sion ET patients during gestation period and perinatal period are at high risk of complications. Evaluation of the prog-nosis, individualized treatment and rational drug use is required, by the cooperation of hematologists and obstetrists.

关 键 词：原发性血小板增多 妊娠期 合理用药 

分 类 号：R965[医药卫生—药理学]